Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies
Peter Haddad, Cecilia Brain, Jan Scott
Patient Related Outcome Measures (2014), pp. 43-43
Open Access | Times Cited: 515

Showing 1-25 of 515 citing articles:

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Thomas R. E. Barnes, Richard Drake, Carol Paton, et al.
Journal of Psychopharmacology (2019) Vol. 34, Iss. 1, pp. 3-78
Open Access | Times Cited: 513
Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness
Dawn I. Velligan, Martha Sajatovic, Ainslie Hatch, et al.
Patient Preference and Adherence (2017) Vol. Volume 11, pp. 449-468
Open Access | Times Cited: 274
Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives
Frederick C. Nucifora, Edgar Woznica, Brian J. Lee, et al.
Neurobiology of Disease (2018) Vol. 131, pp. 104257-104257
Open Access | Times Cited: 229
The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses
Peter Haddad, Christoph U. Correll
Therapeutic Advances in Psychopharmacology (2018) Vol. 8, Iss. 11, pp. 303-318
Open Access | Times Cited: 202
Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
Charmi Patel, Bruno Émond, Marie‐Hélène Lafeuille, et al.
Drugs - Real World Outcomes (2019) Vol. 7, Iss. 1, pp. 19-29
Open Access | Times Cited: 180
Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia
Joris Berwaerts, Yanning Liu, Srihari Gopal, et al.
JAMA Psychiatry (2015) Vol. 72, Iss. 8, pp. 830-830
Closed Access | Times Cited: 179
Clinical translation of long-acting drug delivery formulations
Wei Li, Jie Tang, Dennis Lee, et al.
Nature Reviews Materials (2022) Vol. 7, Iss. 5, pp. 406-420
Closed Access | Times Cited: 128
Solid implantable devices for sustained drug delivery
Elizabeth Magill, Sara Demartis, Elisabetta Gavini, et al.
Advanced Drug Delivery Reviews (2023) Vol. 199, pp. 114950-114950
Open Access | Times Cited: 71
Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development
Toby Pillinger, Oliver Howes, Christoph U. Correll, et al.
The Lancet Psychiatry (2023) Vol. 10, Iss. 11, pp. 860-876
Open Access | Times Cited: 63
Long-acting parenteral drug delivery systems for the treatment of chronic diseases
Anil B. Jindal, Atharva R. Bhide, Sagar Salave, et al.
Advanced Drug Delivery Reviews (2023) Vol. 198, pp. 114862-114862
Closed Access | Times Cited: 48
Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder
Mallik Greene, Tingjian Yan, Eunice Chang, et al.
Journal of Medical Economics (2017) Vol. 21, Iss. 2, pp. 127-134
Closed Access | Times Cited: 169
Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: A systematic review
Siew Ching Ho, Huey Yi Chong, Nathorn Chaiyakunapruk, et al.
Journal of Affective Disorders (2015) Vol. 193, pp. 1-10
Closed Access | Times Cited: 150
Rehabilitation Interventions to Promote Recovery from Schizophrenia: A Systematic Review
Laurent Morin, Nicolás Franck
Frontiers in Psychiatry (2017) Vol. 8
Open Access | Times Cited: 137
Medication nonadherence in bipolar disorder: a narrative review
Ibrahim Jawad, Stuart Watson, Peter Haddad, et al.
Therapeutic Advances in Psychopharmacology (2018) Vol. 8, Iss. 12, pp. 349-363
Open Access | Times Cited: 133
Medication adherence in patients with schizophrenia
Stephanie V. Phan
The International Journal of Psychiatry in Medicine (2016) Vol. 51, Iss. 2, pp. 211-219
Open Access | Times Cited: 109
Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study
Diego Novick, William Montgomery, Tamás Treuer, et al.
BMC Psychiatry (2015) Vol. 15, Iss. 1
Open Access | Times Cited: 106
Insight and medication adherence in schizophrenia: An analysis of the CATIE trial
Julia Kim, Miracle Ozzoude, Shinichiro Nakajima, et al.
Neuropharmacology (2019) Vol. 168, pp. 107634-107634
Closed Access | Times Cited: 103
Technological Interventions for Medication Adherence in Adult Mental Health and Substance Use Disorders: A Systematic Review
Jackson Steinkamp, Nathaniel Goldblatt, Jacob T. Borodovsky, et al.
JMIR Mental Health (2018) Vol. 6, Iss. 3, pp. e12493-e12493
Open Access | Times Cited: 98
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
Markku Lähteenvuo, Jari Tiihonen
Drugs (2021) Vol. 81, Iss. 11, pp. 1273-1284
Open Access | Times Cited: 96
Caregiver Burden Among Caregivers of Individuals With Severe Mental Illness: Testing the Moderation and Mediation Models of Resilience
Zamzaliza Abdul Mulud, Geraldine McCarthy
Archives of Psychiatric Nursing (2016) Vol. 31, Iss. 1, pp. 24-30
Closed Access | Times Cited: 93
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics
Dominic Pilon, Neeta Tandon, Marie‐Hélène Lafeuille, et al.
Clinical Therapeutics (2017) Vol. 39, Iss. 10, pp. 1972-1985.e2
Open Access | Times Cited: 90
Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis
Dee Lin, Philippe Thompson‐Leduc, Isabelle Ghelerter, et al.
CNS Drugs (2021) Vol. 35, Iss. 5, pp. 469-481
Open Access | Times Cited: 85
Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3‐month formulation in patients with schizophrenia: A phase‐1, single‐dose, randomized, open‐label study
Paulien Ravenstijn, Bart Remmerie, Adam Savitz, et al.
The Journal of Clinical Pharmacology (2015) Vol. 56, Iss. 3, pp. 330-339
Closed Access | Times Cited: 80
Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia
Eduard Parellada, Miquel Bioque
CNS Drugs (2016) Vol. 30, Iss. 8, pp. 689-701
Closed Access | Times Cited: 77
Improving Current Treatments for Schizophrenia
Nadja P. Marić, Milica Jovičić, Marina Mihaljević, et al.
Drug Development Research (2016) Vol. 77, Iss. 7, pp. 357-367
Closed Access | Times Cited: 76
Page 1 - Next Page

Scroll to top